ISIS 304801

Phase 2Small molecule

NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

ISIS 304801 is one of 4 small molecule programs targeting Partial Lipodystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Partial LipodystrophyActive, not recruiting

Partial LipodystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Partial Lipodystrophy

#DrugCompanyPhaseTrials

Myalept

Chiesi Farmaceutici S.p.A.

Phase 3

3 2

Mounjaro

Eli Lilly

Phase 2

1 3

Imcivree

Rhythm Pharmaceuticals

Phase 2

1 4

ISIS 304801

NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Partial Lipodystrophy1 trial

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02639286·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ISIS 304801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ISIS 304801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ISIS 304801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

ISIS 304801

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Partial Lipodystrophy1 trial

References

Drug Info

Quick Facts

Related News